US Patent Application 20090041742 - HUMAN DNASE II
InventorsAssigneeUS Classes424/94.6, Hydrolases (3. ) (e.g., urease, lipase, asparaginase, muramidase, etc.)536/23.2, Encodes an enzyme435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/195, Hydrolase (3. )530/387.9Binds specifically-identified amino acid sequenceAttorney, Agent or FirmInternational ClassesA61K 38/46C07H 21/04 C12N 15/63 C12N 5/00 C12P 21/06 C12N 9/14 C07K 16/00 Claims1. An isolated nucleic acid molecule -comprising a nucleotide sequence encoding the amino acid- sequence shown in FIG. 1 for mature human DNase II. 2. An expression vector comprising a nucleotide sequence of claim 1 encoding the amino acid sequence shown in FIG. 1 for mature human DNase II operably linked to a promoter recognized by a host cell transformed with the vector. 3. The isolated nucleic acid molecule of claim 1 comprising a nucleotide sequence that encodes an amino acid sequence having at least 95% identity with the amino acid sequence shown in FIG. 1 for mature human DNase II. 4. The isolated nucleic acid molecule of claim 3 comprising a nucleotide sequence that encodes an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 for mature human DNase II by the substitution of one amino acid for another at only a single position within the FIG. 1 sequence. 5. The isolated nucleic acid molecule of claim 3 comprising a nucleotide sequence that encodes an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 for mature human DNase II by the substitution of one amino acid for another at only two positions within the FIG. 1 sequence. 6. A host cell transformed with an expression vector of claim 2 comprising a nucleotide sequence encoding the amino acid sequence shown in FIG. 1 for mature human DNase II. 7. A method for producing human DNase II comprising:(a) transforming a cell containing an endogenous human DNase II gene with a homologous DNA comprising an amplifiable gene and a flanking sequence of at least about 150 base pairs that is homologous with a DNA sequence within or in proximity to the DNase II gene, whereby the homologous DNA integrates into the cell genome by recombination;(b) culturing the cells under conditions that select for amplification of the amplifiable gene, whereby the human DNase II gene is also amplified; and thereafter(c) recovering human DNase II from the cells. 8. An isolated polypeptide comprising the amino acid sequence shown in FIG. 1 for mature human DNase II. 9. An isolated polypeptide comprising an amino acid sequence having at least 95% identity with the amino acid sequence shown in FIG. 1 for mature human DNase II, which polypeptide has DNA-hydrolytic activity. 10. The isolated polypeptide of claim 9 comprising an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 for mature human DNase II by the substitution of one amino acid for another at only a single position within the FIG. 1 sequence. 11. A polypeptide of claim 12 wherein the amino acid substitution creates a glycosylation site within the polypeptide that is not present in naturally-occurring human DNase II. 12. An antibody that is capable of binding to the amino acid sequence shown in FIG. 1 for mature human DNase II. 13. The antibody of claim 16 that is a monoclonal antibody. 14. A method for the treatment of a patient having a pulmonary disease or disorder comprising administering to the patient a therapeutically effective amount of human DNase II according to claim 9. 15. The method of claim 18 wherein the disease or disorder is cystic fibrosis. 16. A method for the treatment of a patient having systemic lupus erythematosus comprising administering to the patient a therapeutically effective amount of human DNase II according to claim 9. |
| ||||||||||||||
